$NAGE News

HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)

Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Expects 2026 Net Sales To Increase Between 10-15% YoY, Excluding 2025 Net Sales Attributable To The Analytical Reference Standards And Services Segment

Niagen Bioscience Rolls Out Its Clinician-Directed Telehealth Platform Under Niagen Plus In U.S.

Insider Decision Unfolding At Niagen Bioscience: CEO Robert Fried Exercises Options(CORRECTED)

Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K

Niagen Bioscience Partners With Olympia Pharmaceuticals, An FDA-Registered 503B Outsourcing Facility, To Compound And Distribute Pharmaceutical-Grade Niagen

Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K

Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Niagen: High-Quality Growth At A Fair Price

Promising Penny Stocks To Consider In March 2026

March 2026's Promising Penny Stocks To Watch

Discovering Opportunities: Clean Energy Fuels And 2 Other Promising Penny Stocks

Payoneer Global And 2 Promising Penny Stocks To Watch

Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist

Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist

How The Niagen Bioscience (NAGE) Story Is Shifting Around Price Targets And Injectables Potential

Niagen Bioscience Increases Share Repurchase Program to $20 Million